Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 64

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 64
---
,162 for the three months ended September 30, 2025 and 2024, respectively. Cost of
sales includes product costs and labor and overhead related to the sale of our Spryng® products and product costs related to the
sale of PrecisePRP™ products. The increase in our cost of sales in the three months ended September 30, 2025, compared to the three
months ended September 30, 2024, is due to sales of PrecisePRP™ products.

 27 

Operating
Expenses. Operating expenses were $2,285,425 and $2,352,598 for the three months ended September 30, 2025 and 2024, respectively.
The decrease is primarily due to decreased general and administrative (“G&A”) expenses and research and development (“R&D”)
expenses.

General
and administrative (“G&A”) expenses were $1,236,730 and $1,267,117 for the three months ended September 30, 2025 and
2024, respectively. General and administrative expenses include compensation and benefits, contracted services, legal and consulting
fees, and stock compensation expenses.

Sales
and marketing expenses were $787,262 and $620,307 for the three months ended September 30, 2025 and 2024, respectively. Sales and
marketing expenses include compensation, consulting, tradeshows, and stock compensation costs to support the launch of our
Spryng® and the PrecisePRP™ products.

Research
and development (“R&D”) expenses were $261,433 and $465,174 for the three months ended September 30, 2025 and 2024, respectively.
The decrease was primarily related to decreased clinical studies due to tight cash flow constraints.

Operating
Loss. As a result of the foregoing, our operating loss was $2,065,367 and $2,173,040 for the three months ended September 30,
2025 and 2024, respectively. The decrease was related to cost-cutting initiatives in general and administrative and research and development
expenses.

Other
Income (Expense). Other income (expense) was ($942,442) for the three months ended September 30, 2025 compared to other expense
of ($2,453) for the three months ended September 30, 2024. Other income (expense) in 2025 consisted of unrealized loss on change in derivative
liabilities, amortization of